In another paper, Garofalo et al. reported that c-Met expression downregulates miR-103 and miR-203, inducing gefitinib resistance, and epithelial−mesenchymal transition in non-small cells lung cancer (NSCLCs). Here, MET is linked to non-small cell lung carcinoma.